- Home
- EXEL vs TKO Comparison
EXEL vs TKO Comparison
Compare EXEL & TKO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- TKO
- Stock Information
- Founded
- EXEL 1994
- TKO 1980
- Country
- EXEL United States
- TKO United States
- Employees
- EXEL 1147
- TKO N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- TKO
- Sector
- EXEL Health Care
- TKO
- Exchange
- EXEL Nasdaq
- TKO Nasdaq
- Market Cap
- EXEL 11.3B
- TKO 13.3B
- IPO Year
- EXEL 2000
- TKO N/A
- Fundamental
- Price
- EXEL $40.37
- TKO $174.99
- Analyst Decision
- EXEL Buy
- TKO Strong Buy
- Analyst Count
- EXEL 18
- TKO 14
- Target Price
- EXEL $39.59
- TKO $163.77
- AVG Volume (30 Days)
- EXEL 2.6M
- TKO 910.8K
- Earning Date
- EXEL 08-05-2025
- TKO 08-07-2025
- Dividend Yield
- EXEL N/A
- TKO 0.88%
- EPS Growth
- EXEL 237.58
- TKO N/A
- EPS
- EXEL 2.20
- TKO 1.17
- Revenue
- EXEL $2,298,922,000.00
- TKO $2,850,693,000.00
- Revenue This Year
- EXEL $9.37
- TKO $61.32
- Revenue Next Year
- EXEL $11.05
- TKO $24.18
- P/E Ratio
- EXEL $18.12
- TKO $147.91
- Revenue Growth
- EXEL 24.49
- TKO 10.04
- 52 Week Low
- EXEL $21.36
- TKO $102.46
- 52 Week High
- EXEL $48.85
- TKO $179.09
- Technical
- Relative Strength Index (RSI)
- EXEL 42.39
- TKO 66.93
- Support Level
- EXEL $41.03
- TKO $160.94
- Resistance Level
- EXEL $42.07
- TKO $169.08
- Average True Range (ATR)
- EXEL 0.95
- TKO 4.14
- MACD
- EXEL -0.42
- TKO 1.06
- Stochastic Oscillator
- EXEL 12.85
- TKO 83.27
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About TKO TKO Group Holdings Inc.
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sport and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates the majority of its revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's global live events, sponsorship, and consumer products licensing agreements of UFC-branded products.